Clinical data | |
---|---|
Other names | CJ-11,974; (2S,3S)-2-Diphenylmethyl-3-[(5-isopropyl-2-methoxybenzyl)amino]quinuclidine [1] |
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Excretion | Urine (32%), Feces (51%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C31H38N2O |
Molar mass | 454.658 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ezlopitant ( INN, [1] code name CJ-11,974) is an NK1 receptor antagonist. [2] [3] [4] It has antiemetic and antinociceptive effects. [5] [6] Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued. [2]